Koeppen H - Search Results

1

Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma.

Jubb AM, Ribas A, Sosman JA, McArthur GA, Yan Y, Rost S, Zhao S, Koeppen H. Jubb AM, et al. Among authors: koeppen h. Histopathology. 2013 Sep;63(3):351-61. doi: 10.1111/his.12169. Epub 2013 Jun 26. Histopathology. 2013. PMID: 23802768 Clinical Trial.

2

Overexpression of HER2/neu in solid tumours: an immunohistochemical survey.

Koeppen HK, Wright BD, Burt AD, Quirke P, McNicol AM, Dybdal NO, Sliwkowski MX, Hillan KJ. Koeppen HK, et al. Histopathology. 2001 Feb;38(2):96-104. doi: 10.1046/j.1365-2559.2001.01084.x. Histopathology. 2001. PMID: 11207822

3

Plasmalemmal vesicle-associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor-A (VEGF).

Strickland LA, Jubb AM, Hongo JA, Zhong F, Burwick J, Fu L, Frantz GD, Koeppen H. Strickland LA, et al. Among authors: koeppen h. J Pathol. 2005 Aug;206(4):466-75. doi: 10.1002/path.1805. J Pathol. 2005. PMID: 15971170

4

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.

Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H. Ince WL, et al. Among authors: koeppen h. J Natl Cancer Inst. 2005 Jul 6;97(13):981-9. doi: 10.1093/jnci/dji174. J Natl Cancer Inst. 2005. PMID: 15998951

5

EphB2 is a prognostic factor in colorectal cancer.

Jubb AM, Zhong F, Bheddah S, Grabsch HI, Frantz GD, Mueller W, Kavi V, Quirke P, Polakis P, Koeppen H. Jubb AM, et al. Among authors: koeppen h. Clin Cancer Res. 2005 Jul 15;11(14):5181-7. doi: 10.1158/1078-0432.CCR-05-0143. Clin Cancer Res. 2005. PMID: 16033834

6

Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers.

Gray D, Jubb AM, Hogue D, Dowd P, Kljavin N, Yi S, Bai W, Frantz G, Zhang Z, Koeppen H, de Sauvage FJ, Davis DP. Gray D, et al. Among authors: koeppen h. Cancer Res. 2005 Nov 1;65(21):9751-61. doi: 10.1158/0008-5472.CAN-04-4531. Cancer Res. 2005. PMID: 16266996

7

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.

Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ, Koeppen H. Jubb AM, et al. Among authors: koeppen h. J Clin Oncol. 2006 Jan 10;24(2):217-27. doi: 10.1200/JCO.2005.01.5388. Epub 2005 Dec 19. J Clin Oncol. 2006. PMID: 16365183 Clinical Trial.

8

Predicting benefit from anti-angiogenic agents in malignancy.

Jubb AM, Oates AJ, Holden S, Koeppen H. Jubb AM, et al. Among authors: koeppen h. Nat Rev Cancer. 2006 Aug;6(8):626-35. doi: 10.1038/nrc1946. Epub 2006 Jul 13. Nat Rev Cancer. 2006. PMID: 16837971 Review.

9

Ascl2 and 11p15.5 amplification in colorectal cancer.

Jubb AM, Hoeflich KP, Haverty PM, Wang J, Koeppen H. Jubb AM, et al. Among authors: koeppen h. Gut. 2011 Nov;60(11):1606-7; author reply 1607. doi: 10.1136/gut.2010.231746. Epub 2010 Nov 23. Gut. 2011. PMID: 21106550 No abstract available.

10

Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer.

Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Cobleigh MA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H. Jubb AM, et al. Among authors: koeppen h. Clin Cancer Res. 2011 Jan 15;17(2):372-81. doi: 10.1158/1078-0432.CCR-10-1791. Epub 2011 Jan 11. Clin Cancer Res. 2011. PMID: 21224365 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

179 results

Search Page

Filters